In this Breastcancer.org podcast, Brian Wojciechowski, M.D., Breastcancer.org medical adviser, discusses some of the research that was presented at the 2014 San Antonio Breast Cancer Symposium. Listen to the podcast to hear Dr. Wojciechowski explain: results of a study that found that Aromasin plus ovarian suppression reduced recurrence risk better than tamoxifen plus ovarian suppression in some women diagnosed with early-stage, hormone-receptor-positive disease research that underscored the long-term benefits of tamoxifen for reducing risk in women with a higher-than-average risk of breast cancer who’ve never been diagnosed a study showing that Faslodex worked better than Arimidex as a first treatment for women newly diagnosed with advanced-stage breast cancer research conducted in part by Breastcancer.org that shows that breastfeeding, even for a short time, reduces breast cancer risk more than previously thought why a low-fat diet improved survival in women diagnosed with hormone-receptor-negative breast cancer

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related